Mainz Biomed and OncoVanguard8 Partner to Introduce ColoAlert in South America
OncoVanguard8 provides innovative healthcare products to insurance companies in Peru, Colombia, and Ecuador.
BERKELEY, Calif., and MAINZ, Germany – November 18, 2025 – Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic firm focused on the early detection of cancer, today announced the signing of a Memorandum of Understanding (MOU) with OncoVanguard8, a distributor of oncological innovations. This collaboration aims to introduce ColoAlert®, a DNA-based screening test for colorectal cancer (CRC), to South America, commencing with Peru.
Colorectal cancer remains a widespread, yet largely avoidable, form of cancer worldwide. In the first three markets for launch—Peru, Colombia, and Ecuador—around 17,000 new cases are identified annually, underscoring the urgent need for effective early detection and prevention methods. Introducing a DNA-based CRC screening solution marks a major advancement, promising to significantly boost screening rates, enable prompt diagnosis, and seamlessly support national public health goals of decreasing CRC-related deaths and improving overall population health.
Through their joint MOU, Mainz Biomed and OncoVanguard8 have defined key commercial, legal, and regulatory conditions, along with the market entry strategy for the initial region. These terms are intended to be incorporated into a definitive distribution agreement, expected to be signed in the coming weeks.
For updates, please follow us:
About Mainz Biomed NV
Mainz Biomed creates ready-for-market molecular genetic diagnostic solutions for severe health conditions. Its leading product is ColoAlert®, an accurate, non-invasive, user-friendly diagnostic test for the early detection of colorectal cancer. ColoAlert® is currently available throughout Europe. The company is presently conducting its eAArly DETECT 2 clinical study, a precursor to its pivotal FDA study for regulatory approval in the U.S. Mainz Biomed’s pipeline also features PancAlert, a screening test for early-stage pancreatic cancer that employs real-time Polymerase Chain Reaction (PCR)-based multiplex detection of molecular-genetic biomarkers in blood and stool. To find out more, visit or connect with us on , and ..
About OncoVanguard8
OncoVanguard8 specializes in discovering and deploying innovative healthcare solutions for Latin America, aiming to close the technology gap in cancer prevention and early diagnosis. From its base in Lima, Peru, the firm establishes strategic alliances with insurance providers, hospitals, and healthcare networks to bring in advanced diagnostic tools and foster fair access to new technologies. Active throughout Peru, Colombia, and Ecuador, OncoVanguard8 acts as a regional driver for incorporating worldwide oncology progress into local healthcare infrastructures.
For media questions regarding Mainz Biomed:
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
For investor questions, please reach out to:
Forward-Looking Statements
This press release contains certain “forward-looking statements,” as defined by the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements often include terms like “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” or similar phrases that forecast future events or trends rather than describing historical facts. These forward-looking statements are based on the current evaluation of available information and are subject to various risks and uncertainties. Consequently, reliance on forward-looking statements requires prudence. Because of identified and unidentified risks, actual outcomes could vary significantly from the Company’s anticipated results or forecasts. Factors that could lead to actual results differing substantially from those mentioned in these forward-looking statements include, but are not limited to: (i) not achieving projected development and associated goals; (ii) shifts in relevant laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its present or target markets; and (iv) other risks and uncertainties detailed here, along with those periodically discussed in the Company’s other reports and public filings with the Securities and Exchange Commission (“SEC”). Further details regarding these and other elements that may influence the Company’s expectations and projections are available in its initial SEC filings, such as its annual report on Form 20-F filed on March 31, 2025, and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC documents are publicly accessible on the SEC’s website at www.sec.gov. Any forward-looking statement contained in this press release reflects only the information currently at Mainz Biomed’s disposal and is valid solely as of its creation date. Mainz Biomed is not obligated to publicly update any forward-looking statement, whether written or verbal, that may be issued periodically, whether due to new data, future events, or other reasons, unless legally mandated.
